Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
Clinical trial NCT05176925 · TERMINATED
Trial details
- NCT number
- NCT05176925
- Sponsor
- Fudan University
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-10
- Primary completion
- 2022-06-27
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.